Miyazawa H, Murase N, Demetris A J, Matsumoto K, Nakamura K, Ye Q, Manez R, Todo S, Starzl T E
Department of Surgery, University of Pittsburgh, Pennsylvania 15213, USA.
Transplantation. 1995 Apr 27;59(8):1183-8. doi: 10.1097/00007890-199504270-00018.
Hamster to rat renal xenotransplantation was performed with recipient nephrectomies. Recipients were treated beginning on day 0 with continuous FK 506 monotherapy, a 7-day or open-ended monotherapeutic course of cyclophosphamide (CP), and the two drug regimens combined. CP alone (10 mg/kg/day) prevented a xenospecific antibody response and tripled median survival of the kidney (defined as recipient death) from 6 (control) to 18.5 days whereas FK 506 alone had no effect. The drugs in combination were no better than CP alone (15 days) unless the 5-day course of CP was given at a higher dose (15 mg/kg) and started 3 days preoperatively (79 days). In further experiments, adjuvant measures were added to the minimally effective FK 506/7-day CP regimen which gave a median survival of only 15 days. In the most successful modification, intraoperative antibody depletion by the temporary transplantation of third party hamster liver or en bloc kidneys increased median survival from 15 to 34 and 48 days, respectively. An intraoperative i.v. dose administration of the anticomplement drug K76 instead of antibody depletion increased survival to 26 days. Although the events of kidney rejection were similar to those of heart xenografts and partially forestalled by the antibody inhibiting CP treatment, or by antibody depletion, survival for > 100 days was accomplished in only 5 of 86 treated animals. The poorer survival previously reported with cardiac xenotransplantation is largely explained by the life support requirement of the kidneys. Renal failure was responsible for almost all deaths before 60 days, and subnormal renal failure was a pervasive adverse factor thereafter, frequently caused by pyelonephritis which is suspected to have had an immunologic etiology.
进行了仓鼠到大鼠的肾异种移植,并切除了受体的肾脏。从第0天开始,对受体进行持续的FK 506单一疗法、为期7天或不限疗程的环磷酰胺(CP)单一治疗疗程,以及两种药物联合治疗。单独使用CP(10毫克/千克/天)可预防异种特异性抗体反应,并使肾脏的中位生存期(定义为受体死亡)从6天(对照组)增加两倍至18.5天,而单独使用FK 506则没有效果。联合用药并不比单独使用CP(15天)效果更好,除非CP的5天疗程采用更高剂量(15毫克/千克)并在术前3天开始使用(79天)。在进一步的实验中,在最低有效剂量的FK 506/7天CP方案中添加了辅助措施,该方案的中位生存期仅为15天。在最成功的改良方案中,通过临时移植第三方仓鼠肝脏或整块肾脏进行术中抗体清除,可使中位生存期分别从15天增加到34天和48天。术中静脉注射抗补体药物K76而非进行抗体清除,可使生存期延长至26天。尽管肾脏排斥反应的情况与心脏异种移植相似,并且通过抗体抑制CP治疗或抗体清除可部分预防,但在86只接受治疗的动物中,只有5只生存期超过100天。先前报道的心脏异种移植生存期较差,很大程度上是由肾脏的生命支持需求所解释的。肾衰竭是导致60天前几乎所有死亡的原因,而亚正常肾衰竭在此后是一个普遍存在的不利因素,通常由肾盂肾炎引起,怀疑其具有免疫病因。